UBS AG reissued their buy rating on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a research report released on Friday, 99wallstreet.com reports. The brokerage currently has a $535.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $489.00.

Several other analysts have also issued reports on the company. Citigroup Inc. upped their price objective on Regeneron Pharmaceuticals to $575.00 and gave the company a buy rating in a research note on Friday. BMO Capital Markets set a $491.00 price objective on Regeneron Pharmaceuticals and gave the company a hold rating in a research note on Thursday, August 3rd. Canaccord Genuity set a $522.00 price objective on Regeneron Pharmaceuticals and gave the company a buy rating in a research note on Thursday, August 3rd. J P Morgan Chase & Co restated a hold rating on shares of Regeneron Pharmaceuticals in a research note on Thursday, August 3rd. Finally, Piper Jaffray Companies reaffirmed an overweight rating and issued a $557.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $477.91.

Regeneron Pharmaceuticals (REGN) opened at 470.10 on Friday. The stock’s 50 day moving average price is $499.60 and its 200-day moving average price is $421.63. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $543.55. The firm has a market cap of $49.63 billion, a price-to-earnings ratio of 56.91 and a beta of 1.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.67 by $1.50. The business had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. Regeneron Pharmaceuticals’s revenue was up 21.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.82 earnings per share. Analysts forecast that Regeneron Pharmaceuticals will post $14.06 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Rating Reiterated by UBS AG” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/08/08/regeneron-pharmaceuticals-inc-regn-rating-reiterated-by-ubs-ag.html.

In other Regeneron Pharmaceuticals news, SVP Michael S. Aberman sold 2,269 shares of the stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $532.42, for a total transaction of $1,208,060.98. Following the completion of the sale, the senior vice president now directly owns 9,193 shares in the company, valued at approximately $4,894,537.06. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Joseph L. Goldstein sold 1,000 shares of the stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $482.55, for a total value of $482,550.00. Following the sale, the director now owns 14,000 shares of the company’s stock, valued at $6,755,700. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 59,396 shares of company stock valued at $28,484,734. Company insiders own 10.40% of the company’s stock.

Several hedge funds have recently modified their holdings of the stock. Hartwell J M Limited Partnership purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $401,000. Atria Investments LLC increased its stake in shares of Regeneron Pharmaceuticals by 12.5% in the first quarter. Atria Investments LLC now owns 1,082 shares of the biopharmaceutical company’s stock valued at $419,000 after buying an additional 120 shares in the last quarter. Alpha Windward LLC increased its stake in shares of Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16 shares in the last quarter. Prentiss Smith & Co. Inc. increased its stake in shares of Regeneron Pharmaceuticals by 13.8% in the first quarter. Prentiss Smith & Co. Inc. now owns 751 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 91 shares in the last quarter. Finally, Bank of Montreal Can increased its stake in shares of Regeneron Pharmaceuticals by 55.0% in the first quarter. Bank of Montreal Can now owns 50,819 shares of the biopharmaceutical company’s stock valued at $19,693,000 after buying an additional 18,030 shares in the last quarter. Institutional investors own 66.70% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.